NasdaqGM:ATAIPharmaceuticals
AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders
Eli Lilly has signed a definitive agreement to acquire psychedelic drug developer AtaiBeckley (NasdaqGM:ATAI).
The deal includes upfront cash plus contingent value rights tied to milestones in AtaiBeckley’s BPL-003 and VLS-01 depression programs.
The transaction centers on late stage psychedelic therapies targeting treatment resistant forms of depression.
AtaiBeckley focuses on psychedelic based therapies for mental health, with BPL-003 and VLS-01 in development for depression indications...